- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05905588
Study of Hydrogen-rich Water Compared With Placebo in Type 2 Diabetes Patients
June 6, 2023 updated by: Tongshang Ni, Qingdao University
Efficacy and Safety of Hydrogen-rich Water in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of hydrogen-rich water in type 2 diabetes patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The objective of the study is to evaluate the efficacy and safety of hydrogen-rich water compared with placebo in patients with type 2 diabetes mellitus after 12-week treatment in a randomized, double-blind, placebo-controlled design.
Study Type
Interventional
Enrollment (Estimated)
96
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tongshang Ni, Ph.D
- Phone Number: +86 17354605382
- Email: neetongshang@126.com
Study Locations
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Recruiting
- Qingdao Traditional Chinese Medicine Hospital
-
Contact:
- Tongshang Ni, Ph.D
- Phone Number: +86 17354605382
- Email: neetongshang@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged 18-75 years old and gender of both sex;
- Body mass index 18.5kg/m2 to 40 kg/m2;
- Diagnosed as type 2 diabetes according to the diagnostic criteria of type 2 diabetes established by WHO in 1999;
- Patients with type 2 diabetes whose blood glucose is not well controlled after diet control and exercise therapy for more than 3 months;
- HbA1c 7% to 10%, and fasting venous plasma glucose ≤ 15 mmol/L;
- Be able to understand the procedures and methods of this clinical study, voluntarily participate in and sign the informed consent.
Exclusion Criteria:
- Type 1 diabetes, gestational diabetes, or other specific types of diabetes;
- Screening for having received anti-diabetic drug therapy within 3 months or receiving continuous anti-diabetic drug therapy at any time before screening for more than 3 months;
- History of diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome, lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
- Hyperlipidemia patients with irregular or unstable dose of lipid-lowering drugs;
- Chronic gastrointestinal disorders with obvious digestive and absorption disorders, as well as other endocrine diseases, such as hyperthyroidism, hypercortisolism, acromegaly, etc.;
- Patients with diseases that may worsen due to intestinal flatulence (such as Roemheld syndrome, severe hernia, intestinal obstruction, intestinal surgery and intestinal ulcers);
- Had transient ischemic attack, cerebrovascular accident or unstable angina in the past 6 months; History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery; Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;
- Subjects (taking or not taking antihypertensive drugs) had poor blood pressure control (SBP ≥ 160mmhg, or DBP ≥ 100mmhg);
- Liver disease, ALT or AST > 2 ULN, or TBIL > 2 ULN, and the diagnosis was confirmed within one week;
- Patients with renal function impairment (Cr > 1 ULN or Ccr < 60ml / min) and confirmed by reexamination within one week;
- Had malignancy in the past 5 years, not including basal cell carcinoma;
- History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.);
- Combined use of drugs that affect glucose metabolism, such as glucocorticoids;
- Combined use of Chinese herbal medicine with the effect of regulating blood glucose within 3 months;
- Those who have serious diseases and may be in danger of life during treatment and follow-up;
- Mental and neurological disorders, unable to correctly express their wishes;
- Alcoholics and drug abusers and addicts;
- Women of childbearing age are pregnant, breastfeeding, have pregnancy intentions or have a positive pregnancy test (urine HCG or blood HCG), and should not take effective contraceptive measures during the trial (effective contraceptive measures include sterilization, intrauterine device, oral contraceptive or diaphragm method prescribed by local law);
- Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months;
- Patients with other diseases that the researchers believe will not be able to evaluate or are unlikely to complete the expected course of treatment and follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Patients receive placebo.
|
Patients drink 600mL tap water per day by applying analogue cup for 12 weeks.
This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable.
The dissolved hydrogen concentration is 0 ppm in placebo water.
|
Experimental: Hydrogen-rich water
Patients receive hydrogen-rich water.
|
Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.
The dissolved hydrogen concentration is 5 ppm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glycosylated hemoglobin (HbA1c)
Time Frame: Baseline and Week 12
|
The change in HbA1c from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients with HbA1c <7.0%
Time Frame: At Week 12
|
Percentage of patients reaching HbA1c <7% at Week 12
|
At Week 12
|
Patients with HbA1c <6.5%
Time Frame: At Week 12
|
Percentage of patients reaching HbA1c <6.5% at Week 12
|
At Week 12
|
Change in oxidative stress index and inflammatory index
Time Frame: Baseline and Week 12
|
Serum MDA and SOD, TNF-α, IL-6 quantifications were conducted using commercial kits from baseline to Week 12.
|
Baseline and Week 12
|
Change in fasting plasma glucose (FPG)
Time Frame: Baseline and Week 12
|
The change in FPG from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in 2h-postprandial plasma glucose (2h-PPG)
Time Frame: Baseline and Week 12
|
The change in 2h-PPG from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in fasting plasma insulin
Time Frame: Baseline and Week 12
|
The change in fasting plasma insulin from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in insulin sensitivity and beta cell function assessed by the homeostatic model assessment (HOMA)
Time Frame: Baseline and Week 12
|
The change in HOMA-IR and HOMA-β from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in serum lipid profile
Time Frame: Baseline and Week 12
|
The change in total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in waist circumference
Time Frame: Baseline and Week 12
|
The change in waist circumference from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in body weight
Time Frame: Baseline and Week 12
|
The change in body weight from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in body mass index (BMI)
Time Frame: Baseline and Week 12
|
The change in BMI from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Change in blood pressure
Time Frame: Baseline and Week 12
|
The change in blood pressure from baseline to Week 12 in hydrogen-rich water group compared to Placebo.
|
Baseline and Week 12
|
Number of participants with adverse events as a measure of safety and tolerability
Time Frame: Baseline to Week 12
|
Number of participants with adverse events from baseline to Week 12.
|
Baseline to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Tongshang Ni, Ph.D, Qingdao Universtiy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2023
Primary Completion (Estimated)
August 31, 2023
Study Completion (Estimated)
August 31, 2023
Study Registration Dates
First Submitted
May 27, 2023
First Submitted That Met QC Criteria
June 6, 2023
First Posted (Actual)
June 15, 2023
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 6, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QDU-HD-2023/1803
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Hydrogen-rich water
-
Navy General Hospital, BeijingRecruitingChronic Graft-versus-host DiseaseChina
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
Sun JiaRecruiting
-
Kaohsiung Medical University Chung-Ho Memorial...Active, not recruitingQuality of Life | Pain | Head and Neck Cancer | Oral MucositisTaiwan
-
Palacky UniversityCompletedOxidative Stress | Athletic Performance | Muscle FatigueCzechia
-
Palacky UniversityCompletedOxidative Stress | Athletic Performance | Muscle FatigueCzechia
-
Stony Brook UniversityNatural Wellness Now Health ProductsRecruitingMyalgic Encephalomyelitis/Chronic Fatigue SyndromeUnited States
-
Stony Brook UniversityCompletedChronic Fatigue SyndromeUnited States
-
Stony Brook UniversityNatural Wellness Now Health ProductsRecruitingChronic Fatigue SyndromeUnited States